Global Atherosclerosis Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Atherosclerosis Therapeutics Market was valued at $45.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.5% CAGR, to an estimated market size of $58.8 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global atherosclerosis therapeutics market comprises pharmaceutical interventions and biologic therapies specifically indicated for the management of arterial plaque buildup. This includes lipid-lowering agents (statins, PCSK9 inhibitors, and siRNA), antiplatelet drugs, and anti-inflammatory medications used to prevent cardiovascular events like myocardial infarction and stroke. The scope excludes general surgical hardware but includes interventional drug-device combinations and excludes non-specific antihypertensive treatments unless used as part of a primary atherosclerosis regimen.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Atherosclerosis Therapeutics Market in the period 2025-30:
- The market is experiencing a transformative shift from simple lipid control toward anti-inflammatory and immune-modulating therapies that target the underlying vascular biology.
- Rapid adoption of siRNA technologies and long-acting biologics, such as inclisiran, is improving patient adherence by reducing dosing frequency from daily to bi-annual injections.
- The integration of AI-driven patient stratification and genetic profiling is enabling a transition toward precision medicine for high-risk and statin-intolerant populations.
- An aging global demographic combined with rising rates of metabolic syndrome and diabetes is significantly expanding the eligible patient base for secondary prevention.
- There is an increasing clinical focus on early intervention and cascade screening, particularly in developed markets, to initiate therapy before significant arterial narrowing occurs.
- The rise of digital health tools and wearables is being utilized to monitor medication adherence and real-time cardiovascular risk factors, enhancing long-term therapy outcomes.
- Strategic cross-industry collaborations between pharmaceutical giants and tech firms are accelerating the development of novel mRNA-based treatments aimed at reversing existing plaque.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Statins
- PCSK9 Inhibitors & Biologics
- Antiplatelet Agents
- Other Therapies